Hongwei Xu

Researcher

UAMS

Last publication 2025 Last refreshed 2026-05-16

faculty

25 h-index 177 pubs 8,830 cited

Research Areas

Links

ORCID

OverviewAI-generated summary

Hongwei Xu's research focuses on the molecular mechanisms underlying multiple myeloma and its precursor stages. Recent publications investigate the role of extracellular vesicles, gene signatures for risk prediction, and the impact of specific proteins like Cystatin M/E on bone resorption in the context of multiple myeloma. Xu's work also explores immune microenvironment alterations in multiple myeloma and its precursor stages, utilizing multi-omics approaches and single nuclei multiomic profiling. Additionally, research has examined disparities in survival for Black Americans with multiple myeloma and identified risk factors for myeloma progression in this population. Earlier work includes a systematic review on the effect of tryptophan restriction in irritable bowel syndrome therapy.

Metrics

h-index: 25
Publications: 177
Citations: 8,830

Selected Publications

Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

1 citation DOI OpenAlex
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025)

1 citation DOI OpenAlex
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)

DOI OpenAlex
Single Nuclei Multiomic Profiling of Transcriptional and Chromatin Accessibility of Tumor Cells Underlines Extensive Cis-Regulatory Interaction during Multiple Myeloma Progression (2024)

DOI OpenAlex
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)

DOI OpenAlex
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)

1 citation DOI OpenAlex
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression (2024)

DOI OpenAlex
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)

24 citations DOI OpenAlex
Cystatin M/E ameliorates bone resorption through increasing osteoclastic cell estrogen influx (2024)

1 citation DOI OpenAlex
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024)

36 citations DOI OpenAlex
BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions (2023)

6 citations DOI OpenAlex
High NEK2 expression in myeloid progenitors suppresses T cell immunity in multiple myeloma (2023)

17 citations DOI OpenAlex
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023)

13 citations DOI OpenAlex
A Gene Signature Can Predict Risk of MGUS Progressing to Multiple Myeloma (2023)

DOI OpenAlex
A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance (2022)

DOI OpenAlex